Chabiotech차바이오텍
085660 · KOSDAQ · ₩085660 · 차바이오텍
₩7,030▼ ₩70 (0.99%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 28.4% | 28.7% | 26.3% | 29.0% | 24.2% | 29.8% |
| Operating margin | −5.7% | −3.8% | −5.7% | −1.0% | −5.6% | 1.1% |
| Net margin | 1.1% | −8.7% | −0.8% | −0.9% | −5.6% | −1.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +3.4% | +21.4% | +9.5% | +12.9% | +16.1% | — |
| Operating income growth | −52.6% | +18.3% | −523.8% | +79.7% | −710.3% | — |
| Net income growth | +113.0% | −1,264.3% | +4.5% | +82.3% | −240.4% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 4.0% | −37.3% | −2.8% | −2.9% | −12.7% | −3.1% |
| Return on assets | −1.5% | −6.2% | −0.7% | −0.3% | −4.4% | −1.4% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 178.4% | 214.8% | 205.3% | 162.9% | 146.5% | 93.6% |
| Net debt to equity | −13.9% | 71.7% | 57.4% | 47.3% | 37.1% | 2.2% |
| Current ratio | 88.7% | 67.1% | 71.9% | 83.3% | 108.9% | 136.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Chabiotech / 차바이오텍 / 085660 / KRX:085660
Source: KRX statistical information